BioClin Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:BioClin Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11293
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
BioClin Therapeutics Inc (BioClin) is a clinical stage biotechnology company developing protein therapeutics for genetic disorders. Its lead product candidate B-701 is a human monoclonal antibody which targets the activity of FGFR3 (fibroblast growth factor receptor 3) and does not interact with the other FGFRs used for the treatment of metastatic bladder cancer (urothelial cell carcinoma) and achondroplasia (dwarfism). BioClin conducts clinical studies including B-701 monotherapy, and B-701 in combination with standard-of-care chemotherapy, and also with pembrolizumab, an immune checkpoint inhibitor in patients with metastatic urothelial cell carcinoma and other solid tumors. BioClin is headquartered in San Leandro, California, the US.

BioClin Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 9
Venture Financing 9
BioClin Therapeutics Raises Additional USD20 Million in Series B Financing 9
BioClin Therapeutics Raises USD30 Million in Series B Financing 11
BioClin Therapeutics Secures USD13 Million in Series A Round of Funding 13
BioClin Therapeutics Raises US$6 Million In Venture Financing 14
BioClin Therapeutics Raises USD10 Million in Venture Financing 15
BioClin Therapeutics Inc – Key Competitors 16
BioClin Therapeutics Inc – Key Employees 17
BioClin Therapeutics Inc – Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Corporate Communications 19
Sep 18, 2018: Bioclin Therapeutics announces new leadership to advance late-stage bladder cancer development program 19
Jun 26, 2018: BioClin Therapeutics Names Scott Myers as Chairman to its Board of Directors 20
Jan 09, 2018: BioClin Therapeutics Appoints Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, M.D., as Chief Medical Officer 21
Product News 22
05/17/2018: BioClin Therapeutics Announces Poster Presentation of B-701 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 22
01/09/2018: BioClin Therapeutics Appoints Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, M.D., as Chief Medical Officer 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 2
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
BioClin Therapeutics Raises Additional USD20 Million in Series B Financing 9
BioClin Therapeutics Raises USD30 Million in Series B Financing 11
BioClin Therapeutics Secures USD13 Million in Series A Round of Funding 13
BioClin Therapeutics Raises US$6 Million In Venture Financing 14
BioClin Therapeutics Raises USD10 Million in Venture Financing 15
BioClin Therapeutics Inc, Key Competitors 16
BioClin Therapeutics Inc, Key Employees 17

List of Figures
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
BioClin Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

★海外企業調査レポート[BioClin Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Andromeda Metals Ltd (ADN):企業の財務・戦略的SWOT分析
    Summary Andromeda Metals Ltd (Andromeda), formerly Adelaide Resources Ltd, is a mining and mineral exploration company. The company carries out the business of acquisition, exploration and development of gold, halloysite-kaolin, lithium, and copper deposits in Australia. Its projects include Moonta …
  • Tokyo Printing Ink Mfg Co Ltd (4635):企業の財務・戦略的SWOT分析
    Tokyo Printing Ink Mfg Co Ltd (4635) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Black Hills Power Inc:電力:M&Aディール及び事業提携情報
    Summary Black Hills Power Inc (Black Hills), a subsidiary of Black Hills Corp, is a power company that generates, transmits and distributes electricity. The company generates electricity through coal, gas, and oil resources. Its services include electricity and natural gas transmission and distribut …
  • Wageningen University-製薬・医療分野:企業M&A・提携分析
    Summary Wageningen University (WU), a subsidiary of Wageningen University and Research Centre, is an education and research institution. The university offers bachelors’, masters’ and PhD programs. It specializes in healthy food and living environment domain. WU offers various courses in bachelor of …
  • AFT Pharmaceuticals Pty Ltd-製薬・医療分野:企業M&A・提携分析
    Summary AFT Pharmaceuticals Pty Ltd (AFT Pharmaceuticals) is a manufacturer and distributor medical products. The company provides prescription and non-prescription products. Its products include moisturizers, calcium supplements, scalp ointments, eye drops, cracked heel creams, iron and folic acid …
  • Terex Corporation:企業のM&A・事業提携・投資動向
    Terex Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Terex Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • ICON Health & Fitness, Inc.:企業の戦略・SWOT・財務情報
    ICON Health & Fitness, Inc. - Strategy, SWOT and Corporate Finance Report Summary ICON Health & Fitness, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Hammerson plc:企業のM&A・事業提携・投資動向
    Hammerson plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hammerson plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Varian Medical Systems Inc (VAR):企業の財務・戦略的SWOT分析
    Varian Medical Systems Inc (VAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Sangam (India) Ltd.:企業の戦略・SWOT・財務分析
    Sangam (India) Ltd. - Strategy, SWOT and Corporate Finance Report Summary Sangam (India) Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • PharmaCyte Biotech Inc (PMCB):製薬・医療:M&Aディール及び事業提携情報
    Summary PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex Inc, is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes. The company offers technology is used for the treatment of advanced and inoperable pancreatic cancer and diabetes. It deve …
  • Valener Inc (VNR):企業の戦略的SWOT分析
    Valener Inc (VNR) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Jack Henry & Associates Inc (JKHY):企業の財務・戦略的SWOT分析
    Jack Henry & Associates Inc (JKHY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Chevron Corporation (CVX):石油・ガス:M&Aディール及び事業提携情報
    Summary Chevron Corp (Chevron) is an integrated oil and gas company. It operates in the oil and gas value chain from exploration and production, storage and pipeline transportation to refining, marketing and distribution of oil and gas products. Chevron explores for, produces and transports crude oi …
  • Axela Inc-医療機器分野:企業M&A・提携分析
    Summary Axela Inc (Axela), formerly Axela Biosensors Inc is a provider of optic technology solutions. The company offers Ziplex system, Flow-thru TipChips, panelPlus TipChips, diffractive optics technology, diffractive optics sensors, panelPlus sensors and software products. It offers technical and …
  • Rebiotix Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Rebiotix Inc (Rebiotix), formerly MikrobEX Inc is a clinical stage biotechnology company that develops treatments for debilitating diseases. The company targets various disease conditions using drugs based on its microbiota restoration therapy platform. It lead product candidate RBX2660 is u …
  • Concordia International Corp (CXR)-製薬・医療分野:企業M&A・提携分析
    Summary Concordia International Corp (Concordia), formerly Concordia Healthcare Corp is a healthcare products provider that offers orphan drugs. The company undertakes the management and acquisition of legacy pharmaceutical products, orphan drugs and medical devices for diabetics. Its products compr …
  • Lantheus Medical Imaging Inc-医療機器分野:企業M&A・提携分析
    Summary Lantheus Medical Imaging Inc (Lantheus Medical), a subsidiary of Lantheus Holdings, Inc., develops, manufactures, and commercializes diagnostic imaging agents and products for the diagnosis of conditions that affect heart, brain, lungs and other organs using echocardiography and nuclear imag …
  • TPF SA:企業の戦略的SWOT分析
    TPF SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Epax Norway AS:戦略・SWOT・企業財務分析
    Epax Norway AS - Strategy, SWOT and Corporate Finance Report Summary Epax Norway AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆